Academy

Radiomics in MRI Tumor Analysis

Radiomics refers to the extraction of quantitative features from medical images—such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)—to uncover patterns that may not be visible to the human eye. In oncology, radiomics transforms routine clinical scans into high-dimensional data that can be mined to predict tumor characteristics, therapy response, and patient prognosis. Radiomics sits at the intersection of medical imaging, artificial intelligence, and computational biology.

Key Steps in Radiomics Workflows

• Image Acquisition and Standardization: High-quality, standardized imaging protocols ensure that extracted features are comparable across patients and scanners. For MRI, sequences like T1-weighted (T1WI), T2-weighted, and diffusion-weighted imaging (DWI) are commonly used.
• Segmentation: The tumor or region of interest (ROI) is delineated manually, semiautomatically, or automatically. Accurate segmentation is crucial because all derived features depend on these boundaries.
• Preprocessing: Image preprocessing steps such as bias field correction, normalization, and resampling mitigate variations introduced by different scanners or acquisition settings.
• Feature Extraction: Hundreds to thousands of quantitative descriptors are calculated, typically grouped into categories:
• First-order statistics: Intensity-based metrics like mean, variance, skewness, and entropy across the ROI.
• Shape features: Geometric descriptors such as volume, surface area, compactness, and sphericity.
• Texture features: Metrics from gray-level co-occurrence matrix (GLCM), gray-level run-length matrix (GLRLM), gray-level size zone matrix (GLSZM), and more.
• Feature Selection: To avoid overfitting and reduce computational cost, algorithms like LASSO (Least Absolute Shrinkage and Selection Operator), tree-based importance ranking, or mutual information filter out redundant or non-informative features.
• Model Building: Selected features feed into machine learning classifiers—such as logistic regression, random forest, XGBoost—or deep learning models to predict outcomes like tumor grade, molecular subtype, or patient survival.
• Validation and Interpretation: Models should be validated on independent cohorts using metrics like area under the ROC curve (AUC), accuracy, and calibration curves. Tools like SHAP (SHapley Additive exPlanations) provide transparent explanations of feature contributions.

Applications in Glioma and Brain Tumors

In high-grade gliomas, radiomics can noninvasively predict tumor grade (III vs. IV) and identify imaging biomarkers of aggressiveness. Specific texture features—such as SizeZoneNonUniformity and Inverse Variance—correlate with tumor heterogeneity and cellular density. When combined with machine learning algorithms like XGBoost and ensemble techniques such as stacking fusion, radiomics models achieve high accuracy (AUC ≥0.90) in grading and can forecast patient survival, aiding treatment planning and monitoring.

Constraints and Future Directions

• Standardization: Harmonizing imaging protocols and feature extraction routines is essential for multi-center studies.
• Interpretability: Integrating explainable AI methods, like SHAP, helps clinicians trust radiomics-based decisions.
• Multi-omics Integration: Future work will combine radiomics with genomics, proteomics, and metabolomics to build comprehensive predictive models.
• Clinical Translation: Prospective trials are needed to validate radiomics signatures and integrate them into routine workflows for personalized oncology.

Radiomics bridges medical imaging and artificial intelligence, offering a data-driven path toward precision diagnostics and prognostics in oncology. By quantifying tumor phenotypes, radiomics contributes to improved patient stratification and individualized treatment strategies.